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SUMMARY 
With 67% of the world’s human immunodeficiency virus (HIV) infected population 
existing in Sub-Saharan Africa and recent access to highly active antiretroviral therapy 
(HAART); demand for plastic surgical intervention in addressing HIV-associated 
lipodystrophy has expanded dramatically.  This study assessed the prevalence of 
lipodystrophy in a random clinic cohort, the demand for surgical correction, and risk of 
treatment non-compliance 
 
A questionnaire and database cross-sectional review of 554 patients was performed over a 
three-month period at the Themba Lethu Clinic, Johannesburg, South Africa.   
 
A total of 479 patients completed the questionnaire, 83% were female. Nearly 90% of 
patients were currently being treated, or had been treated with stavudine (d4T). The 
prevalence of lipodystrophy was 11.7%.  Nearly 5.9% of patients had considered stopping 
treatment due to changes in body morphology following the onset of HAART, 47% of 
patients interviewed would consider surgery to correct unwanted physical changes 
following treatment with HAART.  Male patients were satisfied by physical changes in 
their body habitus following treatment (pre-treatment satisfaction 38% vs. post-treatment 
satisfaction of 94%).  Female patients had 6.5 times more breast hypertrophy related 
symptoms than in their pretreatment state.  
 
This study identified a prevalence of 11.7% of patients with HIV-associated 
lipodystrophy.  A total of 3.8% of all patients would consider non-compliance on the basis 
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of this side effect alone.  The demand for surgical correction is significant, extends beyond 
patients diagnosed with HIV-associated lipodystrophy, and needs to be addressed. 
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Definitions 
Highly active antiretroviral therapy (HAART): initiated in accordance with the 2004 
South African National Antiretroviral Treatment Guidelines, which include initiation 
criteria of a cluster of differentiation (CD4) count " 200 cells/mm3 or World Health 
Organisation (WHO) stage 4 and Acquired Immunodeficiency Syndrome (AIDS) defining 
illness irrespective of CD4 count.  First line therapy consisted of stavudine (d4T), 
lamivudine (3TC) and efavirenz (EFV) or nevirapine (NVP); however kaletra 
(ritonavir/lopinavir) was used as part of the first line therapy regimen if there were contra-
indications to other first line drugs. Single drug substitutions were permitted depending on 
the underlying clinical presentation of the patient.1 
 
Lipodystrophy: defined as lipoaccumulation or lipoatrophy, was based on the 
development of peripheral fat wasting (face, arms, buttocks or thighs) and/or central 
abdominal fat accumulation and may include enlarged breasts.2 
 
Stigmatization: is defined as the action of branding, marking, scarring or blemishing or to 
mark with stigmata3. 
 
Compliance: is the action of complying with a regimen.  In terms of HAART, compliance 
is considered 100% intake of one’s prescribed daily pills for each drug4.  
 
Gynaecomastia: (“women’s breast”) is defined as the physiological or pathological 
development of breast tissue in men.5
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Chapter 1.  Introduction and Literature review 
1.1   Overview of lipodystrophy 
Lipodystrophy is a term used to describe a heterogeneous group of disorders characterized 
by fat accumulation or atrophy, which may be classified as generalized, partial (extensive 
but not generalized) or localized (limited to a specific area).  They may be congenital or 
acquired disorders.  The function of adipose tissue is for padding and cushioning, but it 
also has an endocrine and metabolic role, secreting leptin, tumour necrosis factor-! (TNF-
!), adiponectin and interleukins.  Consequently, lipodystrophies are associated with 
metabolic derangements including hypertension, insulin-resistance, dyslipidemia and 
coronary artery disease, commonly termed metabolic syndrome.6 
 
1.2 Familial lipodystrophies 
Familial lipodystrophies are conditions that demonstrate Mendelian inheritance patterns 
and may be inherited as a dominant or recessive trait.  Clinical presentation is a direct 
result of adipocyte apoptosis or dysfunctional lipid storage resulting from specific gene 
mutations.  They may present from birth to puberty and may be either generalized or 
partial.   
  
1.2.1  Familial generalized lipodystrophy – Berardinelli Seip syndrome 
An autosomal recessive (AR) condition that affects males and females equally.  Onset is at 
birth.  There are 3 types.  Types 1 and 3 have generalized lipoatrophy but retain palmar 
and periorbital fat (mechanically active fat), while type 2 has lipoatrophy not sparing any 
region.  Metabolic derangements include insulin resistance, diabetes and 
hypertriglyceridemia.  An increased metabolic rate is noted.  Systemic manifestations 
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include cardiomyopathy, liver cirrhosis and liver failure, proteinuric nephropathy and 
acute pancreatitis.6 
 
1.2.2  Familial partial lipodystrophy - Kobberling-Dunnigan syndrome 
An autosomal dominant (AD) condition affecting females more commonly that males.  
Onset is at puberty.  Patients manifest with lipoatrophy of limbs and trunk, and 
lipohypertrophy of faces and neck.  Associated metabolic derangements include insulin 
resistance, diabetes mellitus, hypertriglyceridemia and reduced high density lipoprotein 
(HDL).  Patients may develop acute pancreatitis, steatohepatitis, liver cirrhosis and 
menstrual abnormalities.6 
 
1.2.3  Familial partial lipodystrophy with mandibulacral dysplasia 
A condition with childhood onset and AR inheritance.  Males are more commonly 
affected than females.  There may be partial lipoatrophy involving the extremities but in 
some cases lipoatrophy may be generalized.  There is associated insulin resistance, 
diabetes mellitus, hypertriglyceridemia and reduced HDL.  There is also premature 
ageing, mandibular, clavicular and terminal phalangeal hypoplasia and short stature.  Skin 
acquires a scleroderma like appearance with mottled pigmentation.6  
 
1.3 Acquired lipodystrophy 
The acquired lipodystrophies have varying aetiologies, including iatrogenic, traumatic, 
infective and autoimmune causes.  Patients are affected at any age. Clinical presentation is 
directly related to the underlying cause, and underlying medical conditions and therapeutic 
modalities should be sought in order for a diagnosis to be made. 
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1.3.1 Acquired generalized lipodystrophy - Lawrence syndrome 
This condition affects patients at adolescents and childhood.  Females are affected three 
times more commonly than males.  There is atrophy of face, trunk and limb fat with 
sparing of bone marrow fat.  Around 33% of patients have a preceding autoimmune 
disorder (Sjögrens, dermatomyositis), which suggests there may be an underlying 
autoimmune aetiology to this condition.6 
 
1.3.2  Acquired partial lipodystrophy - Barraquer-Simons syndrome 
Affects females more commonly than males (3:1). This condition commonly occurs in 
childhood and adolescence, although it can rarely develop in adulthood.  There is often an 
initial febrile illness, followed by progressive lipoatrophy in a cephalocaudal distribution, 
with lipohypertrophy in a caudal – cephalic direction.  There are also hemi-lipodystrophy 
forms.  Insulin resistance, diabetes mellitus, and hypertriglyceridemia are associated with 
the disease.   There may also be co-existent autoimmune disorders such as Sjögrens, 
systemic lupus erythematosis (SLE) and dermatomyositis as well as mesangiocapilliary 
glomerulonephritis.6 
 
1.3.3  Acquired localized lipodystrophy 
This is a heterogeneous group of disorders.  Infective causes include pyogenic abscesses 
and localized panniculitis.  Systemic autoimmune disorders may manifest with localized 
lipoatrophy, such as SLE and dermatomyositis.  Trauma and pressure may result in 
localized lipoatrophy.  Various injections may cause localized lipodystrophy including 
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hormones (insulin, corticosteroid and growth hormone), methotrexate, heparin, iron and 
vaccinations (Diphtheria-pertussis-tetanus).6 
 
1.4  HAART-associated lipodystrophy 
This is an acquired, partial form of lipodystrophy.  It is a consequence of the standard of 
care for HIV-positive patients, namely highly active antiretroviral therapy (HAART).  The 
use of HAART has significantly reduced the morbidity and mortality associated with HIV 
infections.  The morbidity of HIV-associated lipodystrophy is now becoming apparent 
with implications on social, sexual and psychological functioning, all of which may result 
in decreased treatment compliance. 
 
1.4.1  Prevalence  
The prevalence of lipodystrophy in various population groups being treated with 
combination therapy, protease inhibitor (PI) and nucleoside reverse transcriptase inhibitor 
(NRTI), has been quoted in a number of studies and varies widely (see Table 1).  One of 
the earliest reports of d4T-related lipodystrophy compared the prevalence of lipodystrophy 
among patients on d4T-based regimens (63%), to patients on zidovudine (AZT) -based 
regimens (18,75%).  The study looked at a cohort of 43 patients.7 A Korean study found 
the prevalence of lipodystrophy to be  3.5% among a clinic population of 156 patients, and 
questioned whether the Asian racial group were somehow protected from developing 
HIV-associated lipodystrophy.8  Other studies performed in Africa reported prevalence of 
34% in Rwanda and 30% in Benin.9,10 
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Table 1. Prevalence of lipodystrophy in previously published studies.9,10,11,12  
Study name Number of 
patients 
Definition Study type Prevelance 
HOPS 1077 (87% 
male) 
Moderate to severe 
lipoatrophy or 
lipohypertrophy 
Cross-sectional: 
- Clinical 
examination 
- Questionaire 
- Database 
49% 
APS 1348 (97% 
male) 
Lipoatrophy and 
lipohypertrophy 
Cross-sectional: 
- Clinical 
examination 
- Questionaire 
- DEXA scan 
- CT scan 
53% 
SALSA 526 (84% male) Lipoatrophy and 
lipohypertrophy 
Cross-sectional:    
- Questionaire 
67% 
APROCO 614 (80% male) Lipoatrophy and 
lipohypertrophy 
Cross-sectional: 
- Clinical 
examination 
- Laboratory 
24% 
LIPOCO 154 (100%male) Lipoatrophy and 
lipohypertrophy 
Cross-sectional: 
- Clinical 
examination 
- Laboratory 
- CT scan 
53.2% 
Benin 88 (40.5% male) Lipoatrophy 
Lipohypertrophy 
Metabolic 
syndrome 
Prospective cohort 
(24 months): 
- Clinical 
examination 
-Questionaire 
30% 
Rwanda 409 Lipoatrophy 
Lipohypertrophy 
Neuropathy 
Lactic acidosis 
Cross-sectional 
(18 months): 
- Clinical 
examination 
-Questionaire 
34% 
APROCO Antiproteases Cohorte.  APS Australian Lipodystrophy Prevelance Survey.  
HOPS HIV Outpatients Study.  LIPOCO Lipodystrophie Cohorte.  SALSA Self 
Ascertained Lipodystrophy Syndrome Assessment   
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1.4.2  Risk factors 
Risk factors for the development of lipodystrophy can be divided into host and treatment 
factors.  Host factors include advanced age, female sex, greater nadir of CD4+ count 
(<350), higher viral load (>100,000 copies/ml) at the onset of HAART, higher baseline 
triglyceride levels and coinfection with hepatitis C. Treatment factors include the agent 
used, a longer duration of therapy (>2 years) and greater compliance on therapy.  The 
different groups of  antiretroviral drugs are associated with specific lipodystrophy 
presentations.  NRTIs are associated with lipoatrophy, peripheral fat wasting, as well as 
myopathies, peripheral neuropathies, steatosis, hyperlactataemia, pancreatitis and bone 
marrow toxicity.  PIs are associated with lipoaccumulation, lipid metabolic disorder and 
insulin resistence.  Causative factors may be additive.11 
 
1.4.3  Pathophysiology 
The pathophysiology of lipodystrophy is a complex multifactorial process that includes 
the effect of the drugs on mitochondrial function and adipocyte metabolism, as well as the 
direct effect of the HIV virus’s R-protien.  Furthermore, these factors are modified by the 
age, sex, genetics and inflammatory state of the hoste.  This ultimately results in:  
  
-Impaired preadipocyte differentiation 
-Increased adipocyte apoptosis 
-Impaired lipogenesis and increased lipolysis 
-Mitochondrial toxicity 
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Both NRTIs (particularly d4T, AZT and didanosine), as well as PIs are common offending 
agents.  Different combinations of drugs are thought to result in characteristic clinical 
manifestations.  
 
1.4.4  Clinical presentation 
As in congenital lipodystrophy syndromes, HIV-associated lipodystrophy commonly 
presents with fat redistribution prior to metabolic complications.  Clinical presentation 
includes lipoatrophy of the face, limbs and buttocks.  In the face, wasting of subcutaneous 
fat, buccal, parotid, temporal and Bichat (preauricular) fat pads results in prominent 
zygoma, sunken eyes, exaggerated nasolabial and marionette lines, yielding a cachexic 
appearance.  Lipohypertrophy results in fat deposition in the breasts (in males resulting in 
gynaecomastia), dorsocervical hump (buffalo hump), submental and submandibular areas. 
Abdominal girth increases secondary to increased subcutaneous fat, mesenteric, omental 
and visceral fat deposition.  Clinical presentation may be purely lipoatrophy or 
lipohypertrophy or a combination.  These changes are progressive, non-reversible and 
potentially stigmatizing.    There are accompanying metabolic derangements including 
insulin resistance, type 2 diabetes, reduced HDL cholesterol, hypertriglyceridemia, 
hyperlactataemia and elevated hepatic transaminases.13,14  There may also be boney 
abnormalities such as osteopenia, osteoporosis and avascular necrosis. 
 
1.4.5  Classification 
Only recently has a case definition been developed.13, 15 This consists of 10 parameters 
(clinical, metabolic and radiological) and aims to guide the diagnosis of lipodystrophy.  It 
has been shown to be accurate in 80% of cases when compared to patient and clinician 
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assessments.13, 15 Since this requires access to dual energy x-ray absorptiometry (DEXA) 
and computer tomography (CT) scans, it may be less useful in the resource-limited 
environment.2 Patient self-reporting combined with physical examination remains the 
earliest, cheapest and best method of diagnosing this condition. 
 
1.4.6  Social Implications  
HIV-associated lipodystrophy is related to poor body image, impacts social and sexual 
functioning and other activities of daily living.  Reports suggest patients fear that changes 
in their body habitus jeopardize the confidentiality of their HIV status and this may even 
lead to treatment non-compliance.11, 16-21 
 
1.4.7  Management  
Management of HIV-associated lipodystrophy incorporates prevention and treatment.  
Prevention is facilitated by the choice of a drug regimen less likely to cause lipodystrophic 
side effects.  The treatment modalities for lipodystrophy are medical and surgical in 
nature.  
 
1.4.7.1  Management – Medical 
Patients on HAART should be screened for metabolic derangements.  Smoking cessation 
and lifestyle changes such as exercise and diet may assist in reducing their cardiovascular 
risk.6  Statins and fibrates are beneficial in improving unfavourable lipid profile.  
Metformin and glitazones are recommended for treating type 2 diabetes.6  Once 
lipodystrophy has been diagnosed, regimen change is commonly instituted.  Interrupting 
or changing treatment will not reverse the morphological changes of lipodystrophy, but 
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will merely reduce its progression.19, 22  Diet and exercise may reduce manifestations of 
lipohypertrophy, but adherence to these lifestyle changes remains difficult and the result 
may only be a partial correction.11 The use of systemic therapies to reduce and treat the 
symptoms of lipodystrophy have been investigated, but have yielded disappointing results.  
The use of glitazones, such as rosiglitazones, have shown improved insulin sensitivity and 
adiponectin levels, but worsened lipid profiles.6 Daily subcutaneous growth hormone 
injections improved truncal and visceral adiposity, but also yielded a loss of peripheral 
limb fat, and increased insulin resistance.6, 20  
 
1.4.7.2  Management – Surgical  
Facial lipoatrophy may be managed with the use of autologous fat injection if adipose-rich 
donor sites exist.  Some patients, specifically those with a mixed lipoatrophy and 
lipohypertrophy presentation may have abdominal and flank donor sites that are harvested 
with small liposuction cannulae.  This is prepared and injected into areas of lipoatrophy 
such as temporal wasting, malar fat pads, zygomatic and buccal regions.  This is a cheap 
and effective way of addressing stigmatizing facial lipoatrophy, but may need to be 
repeated in order to attain long term, durable improvement.  Dermal fat grafting has also 
been described.  In this case, de-epithelialised grafts of fat and dermis are tunneled 
through small punch incisions into areas of facial atrophy to improve and camouflage 
contour deformities.24 When there are no donor sites available due to severe generalized 
lipoatrophy, synthetic poly-L-lactic acid and hyaluronic acid facial fillers can be used.11,22 
These are much more expensive in the large volumes that are necessary to yield a benefit 
to the patient.  They may be temporary or permanent.  Permanent fillers have greater risk 
of infection and complications including foreign body reactions.  Temporary fillers are 
!%.!
designed to reabsorb over 3 to 24 months.22   Repeat injections will therefore be required.  
Due to their cost, synthetic fillers are not used in state practice but are freely available in 
private practice.  Alloplastic facial implants are available and have been used to improve 
contour deformities with good effect and equal complication rates as compared to 
immunocompetent patients.20   
 
Lipohypertrophy affecting the breasts and chest, dorsal hump and abdomen are treated 
with traditionally cosmetic body-contouring techniques.  These include breast reduction, 
gynaecomastia resection, liposuction, abdominolipectomy and dorsal hump lipectomy.20, 
23,25 These services are offered in state practice to patients affected by lipodystrophy as 
treatment for the side-effects of HAART.  Cosmetic and functional outcome are good, 
with complication rates equal to that of immunocompetent patients.  Recurrence has been 
noted in some cases.18-20, 22-25   Expectations should be correctly addressed, especially in 
patients with significant intra-abdominal, visceral, and omental fat deposits which cannot 
safely be accessed using current surgical technique.    
 
1.5 Aims of Study 
The aims of this study were to: 
1) Determine the prevalence of lipodystrophy in a random sample of a clinic population in 
South Africa, looking particularly at the side effect of breast hypertrophy in females and 
gynaecomastia in males.   
2) Explore awareness of lipodystrophy as a side effect of HAART. 
3) Assess whether the occurrence of lipodystrophy posed a threat to compliance on 
HAART 
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4) Assess the demand that exists for surgical correction of HIV-associated lipodystrophy 
among study participants.  
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Chapter 2.  Methodology 
2.1  Study population 
A total of 554 patients were interviewed between October and December 2009 at Themba 
Lethu Clinic, Helen Joseph.  This is a public-sector hospital affiliated to the University of 
the Witwatersrand in Johannesburg, South Africa.  It is one of the largest HIV clinics in 
South Africa.  The programme is funded by the South African National and Gauteng 
Departments of Health, with support from Right to Care funded by United States Agency 
for International Development (USAID) and President’s plan for AIDS relief (PEPFAR). 
Inclusion criteria included both genders, a minimum age of 18 years, HAART for longer 
than 6 months and, in females, not having been pregnant in the previous 12 months.  
Patients were approached in the waiting area of the pharmacy and offered the opportunity 
to be enrolled in a study that would take a few minutes of their time.  They were under no 
obligation, were not informed about the study content until they had opted into the study, 
but would be able to withdraw from the study at any time.  Once a patient volunteered to 
enroll in the study, they were taken to an interview room where the study was explained 
and full informed consent taken.  Interviews took an average of 10 minutes to perform.  
Following the interview, the clinic database was used to complete a patient’s history, 
which included demographic profile, medical history, HAART-regimen history, diagnosis 
of lipodystrophy and their most recent CD4+ count, as well as their CD4+ at onset of 
therapy (appendix 2). 
 
2.2  Data collection 
Data was collected during the interview using a questionnaire devised for the study, as 
well as from the clinic electronic database via a medical management software system, 
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Therapy Edge-HIV™ (TE) (Associated Biological Systems, South Africa).  Knowledge, 
attitudes and perceptions of lipodystrophy were assessed.  Male and female chest and 
breast symptoms were assessed using the Gynaecomastia Evaluation Questionnaire and 
the Breast-related Symptoms Questionnaire respectively (both are disease-specific for 
breast/chest enlargement) 26,27.  Patient’s experiences of stigmatization, compliance and 
their demands for surgical correction were examined.  TE was used to collate patient 
demographic data, their past and present HAART regimens and any previous 
lipodystrophy diagnosis made in the clinic setting by one of the clinic’s physicians. 
 
2.3 Data analysis and Statistics 
Patient characteristics at initiation of HAART were summarized using medians and 
interquartile ranges (IQR) for continuous variables and frequencies and proportions for 
categorical variables.  Frequencies and proportions were also used to describe responses to 
the questionnaire.  For the analysis of time to lipodystrophy, person-time accrued from 
time of HAART initiation until the earliest of: 1) lipodystrophy; 2) close of the data set; 3) 
transfer out; or 4) lost to follow-up (4 months late for last clinic visit).  Kaplan-Meier 
curves were used to compare progression to lipodystrophy by exposure group.  An 
estimation of crude and adjusted hazard ratios of progression to lipodystrophy using Cox 
proportional hazards models was made.  Data were analyzed using STATA version 11 
(Stata Corp., College Station, TX, USA).  
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2.4  Ethical approval 
This study and use of Themba Lethu Clinic data was approved by the Human Research 
Ethics Committee (Medical) of the University of the Witwatersrand and the medical 
superintendent of Helen Joseph Hospital. 
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Chapter 3.  Results  
3.1  Baseline Characteristics of the Study Population 
The baseline characteristics of the study group are summarized in Table 2.  A total of 554 
patients were interviewed between October and December 2009.  Of those interviewed, 
479 patients fulfilled the inclusion criteria and were included in the final data set for 
analysis.  Females comprised 83% (n=395) of the study group while 95% (456) of the 
participants were black Africans.  The median age of participation was 35 (IQR 29.8-40.2) 
years and the median CD4 at onset of therapy was 114 cells/mm3 (IQR 48-176).  Nearly 
89% (n=425) of participants had received a d4T-based regimen. 
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Table 2: Baseline characteristics of study participants at initiation of HAART 
 
 
 
Data is expressed as N (%) except for age, baseline CD4 and baseline BMI which are 
expressed as median (IQR) 
W.H.O World Health Organisation clinical staging of HIV/AIDS.  BMI Body mass index 
d4T is a nucleoside analogue reverse transcriptase inhibitor (NRTI) also known as 
stavudine 
  
 Overall Female Male 
Total, n (%) 479 395(82.5%) 84 (17.5%)  
Employed, n (%) 197 (41.1%)   161 (40.8%) 36 (42.9%) 
Alchohol, n (%)    54   (11.3%) 33 (8.4%) 21 (25%)   
Smoking, n (%) 43 (9%) 25 (6.3%)       18(21.4%)                                                              
Black, n (%) 456 (95.2%) 377 (95.4%) 79 (94%) 
Age (years) 34.7 (29.8-40.2) 33.4 (29.1-39.4) 39.2 (34.5-42.8) 
Baseline CD4; 114 (48-176) 119 (55-181) 95 (23-158) 
             < 50, n (%) 114 (23.8%) 84 (73.7%) 30 (26.3%) 
             50 – 200 255 (53.2%) 214 (83.9%) 41 (16.1%) 
             # 200 110 (23%) 97 (88.2%) 13 (11.8%) 
Baseline BMI(kg/m2); 22.6 (19.6-26.8) 23 (20.2-27.8) 19.7 (18.4-23.4) 
            < 18.5, n (%) 58 (15.1%) 40 (69%) 18 (31%) 
            # 18.5 325 (84.9%) 277 (85.2%) 48 (14.8%) 
W.H.O stage I/II, n (%) 317 (66.2%) 269 (68.1%) 48 (57.1%) 
W.H.O stage III/IV, n (%) 162 (34%) 126 (31.9%) 36 (42.9%) 
d4T-based regimen, n (%) 425 (89%) 351 (90%) 74 (88%) 
non-d4T-based regimen, n (%) 50 (11%) 40 (11%) 10 (12%) 
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3.2  Knowledge, Stigma and Compliance 
The majority (78%) of respondents were aware that lipodystrophy is a side effect of 
HAART.  Amongst the 479 patients on therapy, 303 patients (63%) had encountered a 
gain or loss of body mass since commencing HAART.  Of these, 27% (n=72) felt the 
change in mass ‘gave away’ their diagnosis of being HIV positive.   Nearly 47% (n=129) 
would be willing to undergo surgery to reverse these body changes, while 5.9% (n=18) 
were currently considering, or had previously considered stopping HAART to limit further 
impact on their body form.  Therefore, 3.8% of the total cohort of patients on HAART are 
at risk of treatment non-compliance on the basis of this side effect alone.  
 
3.3  Male respondents 
In this cohort, a total of 84 (17.5%) of the patients were male.  When asked about the 
effect that recent changes breast fat composition had on them since starting HAART; 4 
patients (4.7%) admitted to pain/discomfort, reduced self confidence and emotional 
distress, 17 (20.2%) admitted to pain/discomfort, reduced self confidence, emotional 
distress and inability to play sports, 1 patient (1.2%) had both pain/discomfort, reduced 
self confidence, emotional distress, inability to play sports and other psychological issues, 
whereas 53 patients (63.1%) denied any of these mentioned issues.  A pictorial guide was 
used to represent the classification of gynaecomastia as described by Rorhich (see figure 
1).   
 
Around 60.7 % of patients (n=51) described themselves as grade I, 23.8 % (n=20) 
described themselves as grade II, 4.8 % (n=4) described themselves as grade III, none 
thought they were grade IV and 6 % (n=5) felt they had normal chest size and 
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morphology.  A total of four of the patients did not respond.  Therefore, when asked to 
describe their chest shape following treatment, 34.5% of male patients chose at least a 
grade 2 gynaecomastia28,29.  Even in the light of these findings, 38% of male patients 
described themselves as happy with their pre-treatment body habitus (p =0.05) while 94% 
of male subjects described themselves as satisfied with their body morphology following 
six months of treatment.   These findings are demonstrated in table 6. 
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Figure 1. Pictorial description of gynaecomastia for patient’s self assessment 28,29 
 
Which of the following pictures best depicts your chest / breasts wall: 
 
 
 
 
 A !   B !   C !   D ! 
E ! None of the above, my chest / breast is normal  
 
!&.!
3.4  Female respondents 
Complaints of symptomatic breast hypertrophy were 6.5 times more common in females 
following six months of HAART.  This is demonstrated in table 3.  These complaints 
included difficulty in finding an adequate bra size, lower back pain, painful bra straps, 
difficulty participating in sporting activity due to their breast size and shoulder pain.
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Table 3: Female patients’ symptomatic macromastia pre and post HAART 
                                                                                                               
                                                                               Prior to HAART                                                                Post HAART                                      
  
Symptom                                       All the time       Some of the time        Never                  All the time    Some of the time    Never 
 
Upper back pain                           1            25     318          11           115           246 
Bras, clothes don’t fit                    7                     7                  329                        32                40                  296 
Headaches                                   3                       43                  298                        15               165              194 
Breast pain                                  1                       16                 326                         9                  103               249   
Lower back pain                           6                       22                 314                        15                 141               214 
Rashes or itching                          0                       11                 331                        8                   40                 319 
Painful bra-strap grooves               7                         9                   327                        33                  61                  271 
Difficulty in sport activity                8                        9                   326                         83                  38                 247 
Neck pain                                     0                       10                 331                         8                  91                 263 
Shoulder pain                                1                       13                 327                         6                   91                 262 
Difficulty running                           10                       4                   328                       86                    39                 244 
Hands feel pain / numb                   2                        6                   334                          8                  72                 288 
Arm pain                                       2                        9                   331                         6                   77                 284 
 
HAART: Highly active antiretroviral therapy
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3.5  Regional body weight changes 
Patients with and without a formal clinician’s diagnosis of lipodystrophy indicated 
weight gain and weight loss in specific regions of their bodies.  Weight gain was 
mainly identified in the abdomen (n = 212), breast (n = 190) and dorsal cervical hump 
(n=135).  Weight loss was seen in the buttocks (n = 150), lower limbs (n=150), and to 
a lesser extent, the upper limbs (n=44).  (figures 2,3)
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Figure 2.  Male and female participant’s regional weight loss since initiating HAART  
HAART Highly active antiretroviral therapy. L/Limb Lower limb.  U/Limb Upper 
limb. 
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Figure 3.  Male and female participant’s regional weight gain since initiating HAART  
HAART Highly active antiretroviral therapy.  L/Limb Lower limb.  U/Limb Upper 
limb""
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3.6  Prevalence and predictors of lipodystrophy 
The prevalence of lipodystrophy in the cohort was found to be 11.7%.  These patients 
had been diagnosed with lipodystrophy by a physician on previous consultation and 
this diagnosis had been documented on the clinic database.   The prevalence was 
13.7% in females and 2.4% in males (p= 0.004).  The median time to development 
and diagnosis of symptomatic lipodystrophy from the onset of treatment with 
HAART was 12.7 months (IQR 5.8-24.1).  (See figure 3).  In our cohort of 479 
patients, only 50 had not been treated with a d4T-based regimen. A total of three of 
these patients developed lipodystrophy on treatment.  The prevelance of 
lipodystrophy among patients exposed to a d4T-based regimens was 12.4% (n=53).  
The prevelance of lipodystrophy among patients who had not been exposed to d4T 
was 5.8% (n=3).    
 
Table 4 illustrates risk factors identified for the development of lipodystrophy.  In this 
cohort, protective factors included male sex (Hazard ratio ((HR)) 0.12 ((0.03-0.48)) 
p=0.004), with a trend for reduced lipodystrophy in patients who consumed alchohol 
(HR 0.45 (0.14-1.46), p = 0.18), smoked tobacco (HR 0.47 (0.15-1.50), p = 0.20), 
were of older age at the onset of HAART as well patients who had a baseline BMI of 
less than 18.5 at the onset of treatment (HR 0.71 (0.28-1.79), p= 0.46).  Risk factors 
for the development of lipodystrophy included the use of d4T (HR 1.78 (0.55-5.70), p 
= 0.33) and a baseline CD4+ count of less than 50 at the onset of therapy (HR 1.68 
(0.76-3.71) p = 0.20).  
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Figure 4. Kaplan-Meier curve comparing the development of lipodystrophy in 
patients exposed to d4T versus those never exposed to d4T 
HAART  Highly active antiretroviral therapy.  d4T Stavudine 
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Table 4.  Risk factors for the development of lipodystrophy 
                                                        
                                            crude HR (95% CI)                           adjusted HR(95% CI)                            
 
Male                                       0.12 (0.03-0.48) 0.003                     0.12(0.03-0.48)0.003 
Employed                               1.08 (0.63-1.86) 0.78                       -  
Alchohol                                 0.45 (0.14-1.46) 0.18                       -    
Smoking                                  0.47 (0.15-1.50) 0.20                      - 
 
Age  18-35                              1      
         35-55                              0.87 (0.51-1.48) 0.61 
          >55                                0.53 (0.07-3.90) 0.53                      - 
Baseline CD4  
      <50 cells/mm3                             1.68 (0.76-3.71) 0.20                      - 
         50-200                            1.18 (0.56-2.51) 0.66          
       >200                                 1 (ref)                      
Baseline BMI  
       <18.5 kg/m2                                0.71 (0.28-1.79) 0.46                       - 
        !18 .5                              1 (ref)                      
d4T in regimen                        1.87 (0.59-6.01) 0.29                      1.78(0.55-5.70) 0.33 
No d4T in regimen                  1 (ref)                                              1 (ref) 
 
 
 
HR Hazard ratio.  CD4 Cluster of differentiation.  BMI Body mass index.     
d4T Stavudine 
The effect of d4T on lipodystrophy was adjusted for gender.  
The effect of gender on lipodystrophy is adjusted for d4T use. 
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Chapter 4.  Discussion 
4.1  Prevalence 
The prevalence of lipodystrophy at one year of HAART has been quoted as ranging 
from 6% to as high as 67% in international literature.9-12 Literature pertaining to 
lipodystrophy in African patients has show a prevalence of 34% in a Rwandan study 
at 18 months and 30% in Benin at 2 years of treatment.9, 10 The Rwandan study was a 
cross-sectional review using both a questionnaire and clinical assessment to diagnose 
lipodystrophy.  They do not specify their diagnostic criteria.  They looked at 409 
patients, of whom, 90% were on a d4T-based regimen.  Most patients were on both a 
PI and a NRTI’s.  The study out of Benin was a prospective study, undertaken over 24 
months.  They looked at 88 patients, all of whom were HAART-naïve at the onset of 
therapy.  Again, most patients (94%) were on a d4T-based regimen, but in this study, 
no patients received a PI.  They agree that the lack of a standardized clinical 
definition of lipodystrophy results in different findings across studies.  Other 
limitations of this study included its small sample size, lack of PI’s in the treatment 
regimen, and the fact that most patients in the study commenced HAART at a very 
advanced stage of their disease. Their median time to onset of lipodystrophy was 11 
months.  
 
I have assessed a random group at a large South African HIV clinic, and found the 
prevalence of lipodystrophy to be 11.7%.  The mean duration of therapy prior to 
diagnosis was 12.7 months.  In this cohort, patients were diagnosed with 
lipodystrophy by physicians on routine patient follow up.  The diagnosis was 
completely independent of this study.  This diagnosis was based on clinical 
examination, with or without laboratory confirmation in the form of lipogram, lactic 
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acid and diabetic profile and was then captured on the TE system, the clinic database.  
Both the Rwandan and Benin studies used investigators who looked specifically to 
diagnose lipodystrophy.  The large discrepancy in the prevalence may in part be an 
over-diagnosis in these studies, combined with an under-diagnosis in this study. The 
prevalence at the Themba Lethu clinic has been identified through the record review 
of clinicians performing clinical duties, and not tasked with specifically looking for 
lipodystrophy in their patients.  On direct questioning, 27% of the 479 patients would 
consider surgery if it was offered to address changes in their body following treatment 
with HAART, and 17% felt stigmatized by their body habitus following HAART.  
This may represent a higher prevalence of lipodystrophy than had been diagnosed and 
documented. 
 
4.2  Compliance 
Antiretroviral treatment programs aim for compliance as close to 100% as possible.  
The population assessed indicated a high risk of non-compliance (3.8% of the total 
cohort and 5.9% of patients who had noted weight gain or loss on treatment) as a 
direct effect of symptomatic lipodystrophy.  A study of an Italian outpatient cohort at 
45 weeks of treatment identified 21% (n=182) of their cohort defaulting treatment on 
the basis of systemic toxicity.  Within this group of treatment failure, only 1 patient 
(0.1% of the cohort) had stopped their therapy due to developing lipodystrophy30.  In 
a French cohort, 30% of patients who were compliant at four months were non-
compliant at 20 months of treatment. There was a trend (p=0.16) for more non-
compliant patients having been diagnosed with lipodystrophy (71.4%) as compared to 
the compliant group (61.2%)18.  In the Themba Lethu setting, patients may have 
already defaulted therapy on the basis of lipodystrophic symptoms.  These patients 
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would have been excluded from the cohort, as I used a group of patients awaiting 
medication in the pharmacy queue to conduct this study.   
 
4.3  Gender of participants 
Baril et al, and Miller et al. present studies of European, Australian and American 
cohorts that examine the prevalence of lipodystrophy in these population groups.  
They utilise cohorts that were predominantly male.  African cohorts such as the study 
performed in Benin, and the Themba Lethu cohort have predominantly female 
participants.  There may be various reasons for these findings.  HIV-Aids remains a 
disease commonly encountered in homosexual groups in Europe, America and 
Australia.  In Africa, there is equal prevalence among the heterosexual population.  
Furthermore, females are more likely to be screened and referred from the antenatal 
clinic setting.  Females may seek healthcare more often than males, which could 
account for the bias to more female patients in this cohort 9,10,11,12.  
 
4.4  Knowledge of lipodystrophy 
Patients should be well counseled prior to commencing HAART as they should prior 
to undertaking any potentially hazardous medical treatment or procedure.  Only 78% 
of this cohort was aware of lipodystrophy as a side effect of HAART and HIV.  This 
figure suggests more needs to be done to educate patients about this problem.  This 
could include patient-doctor counseling, group counseling and support groups, posters 
and information packages.  
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4.5  Diagnosing lipodystrophy using a questionnaire 
When body mass was assessed, 63% of patients (303 of 479) noted weight gain or 
weight loss once they commenced HAART.  As many as 17% of patients (82 of the 
479) felt this change in body mass was stigmatizing or indicated their HIV status, 
while 27% of participants indicated they would consider surgery to address some of 
the changes in their body habitus resulting after treatment.  This is a greater number 
of patients than the 11.7% who had received a formal diagnosis of lipodystrophy from 
a doctor and had it documented on the TE system.  This highlights a number of issues.  
Weight change on HAART is not only a symptom of lipodystrophy, but of recovery 
from the wasting effect of advanced HIV infection.  As a patient’s immune status 
improves, they are less likely to suffer from opportunistic infections, and will gain 
weight previously lost.  Therefore, simply using weight gain and loss as an indicator 
of lipodystrophy is inaccurate and leads to false positive findings.  As many as 150 
(31%) patients indicated weight loss of their limbs and buttocks, while 190 (39.7%) 
indicated increased fat distribution of their breast and chest.  Furthermore, 212 
(44.3%) indicated increased fat distribution within their abdomen.  Fewer patients 
experienced regional changes in body fat distribution than general weight gain and 
weight loss but this is also higher than the 11.7% who had been diagnosed with 
lipodystrophy. Again, using regional weight gain and weight loss to try determine a 
diagnosis of lipodystrophy is likely to yield false positives and false negatives.  This 
was demonstrated by this study’s attempt to produce a questionnaire that would be 
able to diagnoses HIV-associated lipodystrophy. 
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Table 5: Performance of the questionaire as a lipodystrophy prediction tool 
 
 
 
 
  Test 
(Tool) 
                              
        Disease (lipodystrophy) 
         + ve                          - ve  
 
    Total 
 
    + ve            161        237    398 
    -  ve             63         18      81 
  TOTAL            224       255    479 
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Table 5 depicts the performance of the questionaire as a tool to diagnose 
lipodystrophy.  The questionnaire was shown to have a 72% sensitivity for identifying 
lipodystrophy, but only an 8% specificity.  Using the questionaire, the prevalence of 
lipodystrophy was found to be 46.8%.  The positive predictive value of the test 
questionaire was 41% while the negative predicitive value was 22%.  Accuracy of the 
test was found to be 37%.  The development of lipodystrophy is along a continuum 
from normal to frank lipodystrophic morphology.  In the clinical context of a busy 
clinic, where the managing physicians may not have been focused on making a 
diagnosis of lipodystrophy, a prevelance of 11,7% may be too conservative a value. 
Nearly 17% of patients stated they felt their body morphology was stigmatising  and 
indicative of their status.  This subjective measure may be closer to the real 
prevalence of lipodystrophy within the cohort, or it may represent the category of 
patient with self-percieved stigmatising disease.   
 
4.6  Demand for surgery 
The Themba Lethu cohort indicated a high demand for surgical correction of the 
morphological changes that developed following HAART.  A total of 129 of 479 
patients interviewed (27%) were willing to undergo surgery to improve some of the 
physical changes following HAART.  This included patients who had not been 
diagnosed with lipodystrophy.  Currently, there are no reliable medical treatments to 
reverse lipodystrophy.  Diet and exercise, regimen change and surgery offers the best 
chance at improving this side effect once it has developed.  At the time of writing, no 
other published studies have quantified the demand that exists for surgical correction 
of lipodystrophy. 
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4.7  Stigmatisation 
Stigmatization of HIV+ patients has existed since the early history of the disease and 
continues to this day.   The physical manifestation of lipodystrophy is recognized by 
laymen within communities. It also serves as a constant reminder to the patient that 
they are infected with, and are on treatment for HIV31. In our study, 17% of patients 
on HAART felt their associated weight change could alert others to their diagnosis of 
HIV, regardless of whether they had been diagnosed with lipodystrophy.  Preau et al 
(2008) investigated the high rate of suicide attempts among patients living with HIV 
in France.  They identified a higher rate of suicide attempts among HIV+ patients who 
had lipodystrophy (26%) versus those who did not  (18%).  They attributed this to two 
factors: negative body image and the stigmatization within society32.  
 
4.8 Gynaecomastia and breast hypertrophy 
It has been documented that females are more likely to develop lipodystrophy than 
males.2   This study shows the prevalence of lipodystrophy in males to be 2.4% and in 
females to be 13.7% (p=0.004).  Interestingly, males were more satisfied with their 
body image and habitus following at least 6 months of treatment, even though 29% of 
male respondents described their own chest/breast morphology as at least a grade 2 
gynaecomastia.  Women on the other hand, had a 6.5 times higher rate of 
symptomatic breast hypertrophy complaints following at least 6 months of HAART.  
 
!"#
Table 6: Male psychological experiences pre- and post- HAART 
  
                                                                                                      
                                                                                                    
  
 
                                                                                                         Pre HAART                                                Post HAART 
  
                                                                                 Dissatisfied      Neutral       Satisfied            Dissatisfied    Neutral     Satisfied 
 
1. During social activities:                             42 (50%)         9 (10.7%)     32 (38.1%)          3 (3.6%)      1 (1.2%)   79(94.1%) 
2. Among certain people when dressed:         42 (50%)        11 (13.1%)    34 (40.5%)          3 (3.6%)      1 (1.2%)   79 (94.1%)      
3. Among certain people when undressed:    40 (47.6%)     12 (14.3%)    30 (35.7%)           3 (3.6%)     1 (1.2%)   76 (94.1%)  
 
HAART: Highly active antiretroviral therapy         
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4.9  Risk factors for developing lipodystrophy 
The distribution of weight gain and weight loss in this population was similar to that 
seen in previous studies (Figure 1, 2). 13-15 Since 1999, d4T has been identified as a 
major cause of lipodystrophy33.  In the Themba Lethu cohort, almost all patients had 
received d4T-based treatment regimens (89%).  As a result of the non-d4T group 
being of small numbers, this study is only able to show a trend toward d4T as a risk 
factor (adjusted HR 3.49 range 0.44 – 27.6(p=0.29)).  Patients on non-d4T based 
regimens still develop lipodystrophy (n = 3, 5.8%) but with a lower prevalence than 
patients who had been on d4T-based regimens (n = 53, 12.4%).  This finding is 
demonstrated in table 7 and corresponds with another study from the same unit4.  
Tenofovir (TDF) has replaced d4T in the South African context since 2010.  
Physicians and surgeons can still expect to be confronted with the side effects of 
lipodystrophy from non-d4T based regimens.  
 
Host risk factors for the development of lipodystrophy include advanced age, female 
sex, longer duration of therapy and patients commencing treatment at a later stage in 
their illness. This study found that patients commencing treatment when their BMI 
was less than 18.5, as well as those commencing therapy at an older age, were less 
likely to develop lipodystrophy.  This data concurs with other studies in that the lower 
the CD4 count at onset of therapy, the higher the risk of developing lipodystrophy on 
recovery19, 34-37.  There was also a non-significant trend towards tobacco and alchohol 
use being protective against the development of lipodystrophy.  This may represent a 
real relationship or a population less compliant on therapy.  While the protective 
effect of tobacco use is supported by a previous study of Hispanic HIV+ patients, the 
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finding of a protective effect of alchohol contradicts another study that suggests heavy 
alchohol users may be more likely to develop lipodystrophy while on HAART38,39
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Table 7: Effect of d4T on development of lipodystrophy 
 
Adjusted for gender.  Median time to lipodystrophy = 12.7 months (IQR 5.8-24.1 
months) 
d4T Stavudine.  HR Hazard ratio.  IQR Interquartile ratio 
 
  Total, n (%) Lipodystrophy, n 
(%)  
crude HR adjusted HR 
d4T in regimen 426 (89.1%)     53 (12.4%) 1.87 (0.59-6.01) 
0.29 
3.49 (0.44-27.6) 
No d4T  52 (10.9%)        3 (5.8%)       1 (ref)       1 (ref) 
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Chapter 5.  Study limitations 
The study was limited to 3 months of data collection.  I had initially hoped to 
interview 1000 patients and this was calculated according to an initial 3-day pilot 
study.  Unfortunately, I had not factored into my calculations that the clinic closed 
early on Fridays and closed in mid-December for year-end holidays.  This resulted in 
a loss of 24 out of a possible 66 days of data collection.  Furthermore, of the 554 
patients interviewed, only 479 fulfilled inclusion criteria or had filled in consent 
forms and questionnaires correctly, resulting in 75 participants being excluded from 
the study 
 
Of a total of 479 participants, 83% of were female (395 patients).  The reason as to 
why more females were recruited relative to males is a reflection of different 
attendance at the clinic between the genders.  The reason for this is complexed. 
 
There exists a selection bias among the study sample.  Generally patients commence 
their treatment at the Themba Lethu clinic, and are often ‘stepped down’ to peripheral 
clinics once their treatment regimen has been well tolerated at 18 months.  This means 
that the patients seen at the clinic were more likely to be at an early stage of their 
therapy and may not yet have manifested their symptoms of lipodystrophy.  
Furthermore, patients may have withdrawn from the study if they were not affected 
by the condition that was being discussed, and other affected patients may have been 
drawn to the study once they heard by ‘word-of-mouth’ what the study was 
addressing.  Certainly some patients anticipated they may be candidates for surgery, 
and used the interview as a time to address these requests. 
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There is also a potential for a reporting bias in this study.  I used diagnosis of 
lipodystrophy as that having been made by a physician on a previous consultation and 
noted on the TE system.  There is likely to have been an under-diagnosing or under-
reporting of lipodystrophy in a busy clinic setting.  Certainly, as has been shown, 
there were more patients complaining about unsightly body morphology than the 
number diagnosed with lipodystrophy. 
 
Finally, there may have been an exclusion bias in that patients suffering from severe 
symptoms of lipodystrophy may either have died from metabolic manifestations (such 
as myocardial infarctions), or may have already become non-compliant on treatment 
and no longer be attending clinic.    
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Chapter 6.  Conclusion and recommendations 
6.1  Conclusion 
Breast Hypertrophy and Gynaecomastia in HIV associated lipodystrophy, a 
problematic side-effect of life-saving antiretroviral therapy showed the following: 
• Female patients comprised 82.5% of our study cohort suggesting more female 
patients are treated at the clinic as compared to males. 
• The majority (78%) of respondents were aware that lipodystrophy is a side 
effect of HAART. 
• The incidence of lipodystrophy was found to be 11.7%. 
• A large proportion of patients on HAART (3.8%) considered stopping therapy 
due to the morphological changes resulting from lipodystrophy. 
• Male patients were more satisfied with their body habitus following at least 6 
months of therapy, even though 34.5% indicated at least a grade 2 
gynaecomastia. 
• Female patients complained of symptomatic macromastia 6.5X more often 
following 6 months of HAART.  
• In a busy clinic setting, lipodystrophy may be difficult to diagnose and 
clinically significant cases may be missed by physicians not looking for this 
side-effect. 
• Surgical demand was calculated at 27% of the cohort, these patients were 
willing to undergo surgery to reverse changes in their body habitus following 
HAART. 
• Regional weight gain and weight loss, as well as risk factors and protective 
factors for the development of lipodystrophy were consistent with previously 
published literature.  
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• Most patients have been treated with a d4T-based regimen.  Although this is a 
major offending agent, patients on non-d4T-based regimens still develop HIV-
associated lipodystrophy, albeit at a lower incidence.  Therefore, although d4T 
is no longer offered in HAART regimens in South Africa, we can still expect 
to see cases of lipodystrophy from newer HAART regimens. 
 
6.2  Recommendations: 
• Awareness needs to be raised in the male population to know their HIV-status 
and to seek treatment for their disease. 
• Patients embarking on HAART should be well informed about the side-effects 
of these medications, especially lipodystrophy, which has metabolic and 
morphological implications, and may be stigmatizing and life-threatening. 
• Highly sensitive and specific, non-invasive screening methods for diagnosing 
lipodystrophy in a busy clinic setting need to be developed so that early 
diagnosis and management of these patients can be instituted. 
• Increased awareness of the available treatment options for lipodystrophy is 
necessary.  Non-compliance due to this side-effect would not be considered if 
patients were aware of the treatments available, and felt therapy were easily 
accessible. 
• Due to the large numbers of patients who have and will develop HIV-
associated lipodystrophy, specialised clinics should be set up to manage these 
complexed cases.  Multidisciplinary teams including infectious disease 
specialists, endocrinologists, dieticians, biokineticists, psychologists and 
plastic surgeons should work together to prevent progression, conservatively 
'!#
reduce symptoms, and finally resort to surgical measures to treat these side 
effects. 
• Access to surgery needs to increase if we are to offer meaningful treatment of 
this side effect.  Protocols that determine who qualifies for surgery should be 
established.  Simple weight gain or loss may not be enough reason to operate 
on patients.  Stigmatizing morphology and functionally disabling side effects 
such as massive breast hypertrophy and gynaecomastia warrant surgical 
management.  Dedicated theatre time, specialised body contouring equipment 
and adequate manpower will also need to be provided to address the pending 
epidemic of cases that we are likely to see.
''#
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